Cargando…

Correction: Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes

Detalles Bibliográficos
Autores principales:	Ueno, Masanobu, Miyagawa, Ippei, Miyazaki, Yusuke, Hanami, Kentaro, Fukuyo, Shunsuke, Kubo, Satoshi, Nakayamada, Shingo, Tanaka, Yoshiya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926818/ https://www.ncbi.nlm.nih.gov/pubmed/36788609 http://dx.doi.org/10.1186/s13075-023-03005-x

Ejemplares similares

Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes
por: Ueno, Masanobu, et al.
Publicado: (2022)

PUSTULOTIC ARTHRO-OSTEITIS (SONOZAKI SYNDROME)
por: Su, Ozlem, et al.
Publicado: (2011)

Low Prevalence of Anti-cyclic Citrullinated Peptide Antibodies in Japanese Patients with Pustulotic Arthro-osteitis
por: Ohashi, Takenobu, et al.
Publicado: (2016)

Efficacy of guselkumab in a subpopulation with pustulotic arthro‐osteitis through week 52: an exploratory analysis of a phase 3, randomized, double‐blind, placebo‐controlled study in Japanese patients with palmoplantar pustulosis
por: Yamamoto, T., et al.
Publicado: (2020)

Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis
por: Ueno, Masanobu, et al.
Publicado: (2021)

Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study
por: Ueno, Masanobu, et al.
Publicado: (2022)

Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet’s disease
por: Miyagawa, Ippei, et al.
Publicado: (2019)

Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study
por: Tanaka, Yoshiya, et al.
Publicado: (2015)

Serum TNFα levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study
por: Miyazaki, Yusuke, et al.
Publicado: (2021)

Generation-Dependent Retention Rates and Reasons for Discontinuation of Molecular Targeted Therapies in Patients with Rheumatoid Arthritis: From FIRST Registry
por: Kubo, Satoshi, et al.
Publicado: (2023)

Precision medicine based on the phenotypic differences in peripheral T helper cells in patients with psoriatic arthritis: One year follow-up outcomes
por: Miyagawa, Ippei, et al.
Publicado: (2022)

IgG4-related Pleuritis with Elevated Adenosine Deaminase in Pleural Effusion
por: Nagayasu, Atsushi, et al.
Publicado: (2018)

An Autopsy Case with Cerebral Hemorrhaging due to disseminated Aspergillosis During Glucocorticoid Therapy for Overlap Syndrome of Systemic Lupus Erythematosus and Systemic Sclerosis
por: Ueno, Masanobu, et al.
Publicado: (2018)

Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study
por: Miyagawa, Ippei, et al.
Publicado: (2022)

MENISCAL REPAIR RESULTS COMPARING MRI, ARTHRO-MRI, AND ARTHRO-CT
por: ALMEIDA, ADRIANO MARQUES DE, et al.
Publicado: (2018)

Comprehensive immunophenotypic analysis reveals the pathological involvement of Th17 cells in Graves' disease
por: Torimoto, Keiichi, et al.
Publicado: (2022)

Eosinophilic granulomatosis with polyangiitis exhibits T cell activation and IgG4 immune response in the tissue; comparison with IgG4-related disease
por: Kubo, Satoshi, et al.
Publicado: (2022)

Efficacy and safety of belimumab during maintenance therapy in patients with systemic lupus erythematosus
por: Miyazaki, Yusuke, et al.
Publicado: (2021)

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023)

Th22 Cells Promote Osteoclast Differentiation via Production of IL-22 in Rheumatoid Arthritis
por: Miyazaki, Yusuke, et al.
Publicado: (2018)

Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation
por: Miyazaki, Yusuke, et al.
Publicado: (2020)

Abduction Arthro-Fluoroscopy in Adhesive Capsulitis of the Shoulder
por: Sontou, Regis, et al.
Publicado: (2023)

Efficacy of guselkumab compared with adalimumab for psoriasis: a meta-analysis of randomized controlled studies
por: Fu, Hongyi, et al.
Publicado: (2022)

Five Cases of IgG4-related Disease with Nasal Mucosa and Sinus Involvement
por: Ueno, Masanobu, et al.
Publicado: (2020)

Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023)

Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study
por: Hirata, Shintaro, et al.
Publicado: (2013)

80. Macrophage myofasciitis: a rare cause of severe arthro-myalgias
por: Shabbir, Shabnam S, et al.
Publicado: (2018)

Up-Regulation of TLR7-Mediated IFN-α Production by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus
por: Sakata, Kei, et al.
Publicado: (2018)

Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting
por: Miyazaki, Yusuke, et al.
Publicado: (2021)

Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Blauvelt, Andrew, et al.
Publicado: (2023)

Evaluation of the Glenoid Track Tomographic Method in Magnetic Resonance Imaging/Arthro-MRI
por: Godinho, Andre Couto, et al.
Publicado: (2020)

Guselkumab for plaque psoriasis
Publicado: (2019)

Patient‐reported symptoms and signs of moderate‐to‐severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial
por: Papp, K.A., et al.
Publicado: (2018)

BAFF- and APRIL-targeted therapy in systemic autoimmune diseases
por: Nakayamada, Shingo, et al.
Publicado: (2016)

Immune Phenotype as a Biomarker for Systemic Lupus Erythematosus
por: Nakayamada, Shingo, et al.
Publicado: (2023)

Pancreas-protective effect of rituximab for acute-onset type 1 diabetes in the honeymoon period: a case report
por: Kurozumi, Akira, et al.
Publicado: (2016)

Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis
por: Ishikawa, Yuichi, et al.
Publicado: (2018)

Osteitis Fibrosa
por: Greig, David M.
Publicado: (1920)

Osteitis Pubis
por: Basu, S. P.
Publicado: (1952)

Osteitis Fibrosa
Publicado: (1926)

Cannot write session to /tmp/vufind_sessions/sess_cvjvp7inuo3m777hcmup10u2mm